Subscribe to Finance

The Lead

Personalized medicine market to surpass $60 billion by 2019

June 18, 2015 12:50 pm | by PRESSWIRE | News | Comments

Cutting-edge new research by KellySciPub indicates that the core personalized medicine market will be worth over $60 billion by 2019. This market is made up of companion diagnostics and targeted therapeutics and is currently worth $42 billion.

Bristol-Myers Squibb is an overvalued company in an expensive sector

June 18, 2015 12:35 pm | by Seeking Alpha | News | Comments

In my view, the market is set to crash at a certain point in the future. The reason? If the FED...

Pharmaceutical industry venture capital jumps in 2014

June 18, 2015 11:32 am | by Andy Szal, Digital Reporter | News | Comments

During the first 11 months of 2014, the industry saw $15.3 billion in venture capital compared...

Survey: Americans blame pharmaceutical companies for high drug prices

June 16, 2015 4:11 pm | by Andy Szal, Digital Reporter | News | Comments

The June Kaiser Health Tracking Poll found that nearly three-quarters of respondents believed...

View Sample

FREE Email Newsletter

Axovant doubles in value after $315M IPO

June 12, 2015 10:57 am | by The Associated Press | News | Comments

Shares of Axovant Sciences nearly doubled in value after the dementia drug developer said its initial public offering raised $315 million, more than Axovant had expected.

Diverse asthma treatment pipeline presents major opportunity

June 4, 2015 11:10 pm | by GBI Research | News | Comments

The active and diverse treatment pipeline for asthma boasts a striking level of innovation, with many first-in-class products representing significant investment opportunities, says business intelligence provider GBI Research.

Teva looks to raise stake in Mylan following takeover bid

June 3, 2015 5:21 pm | by Andy Szal, Digital Reporter | News | Comments

The ongoing spat between generic pharmaceutical rivals Teva and Mylan shows no signs of slowing down.


North American market shifting from prescriber to payer

June 3, 2015 11:10 am | by Global Data | News | Comments

GlobalData’s Healthcare Industry Analyst said as overall healthcare spending has slowed during the recession, new pharmaceutical products and medical technologies have received increased attention regarding their potential cost savings.

Insurance broker pleads guilty to stealing $10M from Aetna

June 3, 2015 10:47 am | by The Associated Press | News | Comments

A former insurance broker who stole $10 million from Aetna, Inc. by failing to submit health insurance premiums paid by a New Jersey university has pleaded guilty to fraud.

J&J pipeline forecasting 10 new products worth $1B

June 2, 2015 12:14 pm | by PR Newswire | News | Comments

Senior leaders announced plans to file for regulatory approval of more than 10 new products between 2015 and 2019.

AARP survey shows sharp generic price increases

May 28, 2015 11:02 am | by LINDA A. JOHNSON, AP Business Writer | News | Comments

Reversing a long-term trend, prices for more than one in four generic medicines widely used by older Americans increased in 2013.

Dyadic International Q1 Results

May 15, 2015 11:59 am | by Dyadic International | News | Comments

Dyadic International, Inc. is a global biotechnology company focused on enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical, food and feed industries.


Puma Biotech Stumbles With Breast Cancer Drug

May 15, 2015 11:53 am | by The Associated Press | News | Comments

Treatment results with the breast cancer drug Herceptin, as well as chemotherapy, did improve, but the drug's backers had been hoping to see better results.

TRACON Q1 Results

May 14, 2015 11:29 am | by TRACON Pharmaceuticals | News | Comments

TRACON Pharmaceuticals, a clinical stage biopharmaceutical company, today announced its financial results for the first quarter.

Obamacare Ruling Could Impact States, But Not Lawmakers

May 13, 2015 11:26 am | by Ricardo Alonso-Zaldivar, Associated Press | News | Comments

If the Supreme Court rules the way most Republicans want in the latest health overhaul case, GOP lawmakers who now have insurance coverage under President Barack Obama's law may wind up with some explaining to do.

Vitae Pharmaceuticals Q1 Results

May 13, 2015 11:19 am | by Vitae Pharmaceuticals | News | Comments

Vitae Pharmaceuticals, a clinical-stage biotechnology company, recently provided financial results and pipeline reports for the first quarter of 2015.

Fibromyalgia Treatment Market Slowing

May 13, 2015 11:08 am | by GlobalData | News | Comments

The treatment market value for fibromyalgia across the seven major markets will reach $1.9 billion by 2023, according to research and consulting firm GlobalData.


Novavax Announces Q1 Results

May 8, 2015 10:58 am | by Novavax | News | Comments

Novavax, Inc., a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced Q1 results.

Portola Pharmaceuticals Q1 Results

May 7, 2015 11:35 am | by Portola Pharmaceuticals | News | Comments

Portola Pharmaceuticals today provided a corporate update and reported its financial results for the first quarter.

Alzheimer Treatments Worth $13B by 2023

May 6, 2015 10:53 am | News | Comments

The global market for Alzheimer’s Disease treatment will more than double in value from $4.9 billion in 2013 to reach an estimated $13.3 billion by 2023.

Amyris Unveils Q1 Results

May 6, 2015 10:47 am | by Amyris | News | Comments

Amyris, Inc., the industrial bioscience company, today announced financial results for the first quarter of 2015.

Sagent Unveils Q1 Results

May 5, 2015 11:50 am | by Sagent Pharmaceuticals | News | Comments

Sagent Pharmaceuticals, Inc., a maker of specialty pharmaceutical products with a specific emphasis on the injectable market, today announced financial results for the first quarter.

AMAG Pharmaceuticals Q1 Results

May 5, 2015 11:39 am | by AMAG Pharmaceuticals | News | Comments

AMAG Pharmaceuticals, Inc., a specialty pharmaceutical company, today reported unaudited consolidated financial results for the first quarter of 2015.

Capital Investments: Regulations, Technology and ROI

May 5, 2015 10:45 am | by Jeff Reinke, Editorial director | Blogs | Comments

Pharmaceutical processors face a number of challenges in determining the direction they should take when considering internal investments – but a lack of options have never been amongst them.

Rural Hospitals Struggle to Stay Open, Adapt to Changes

May 4, 2015 11:27 am | by David A. Lieb, Associated Press | News | Comments

Sac-Osage is one of a growing number of rural U.S. hospitals closing their doors, citing a complex combination of factors that have put more financial pressure on facilities.

Medicare Contrast in Generic, Brand Prescribing

May 4, 2015 11:21 am | by Lauran Neergaard, AP Medical Writer | News | Comments

The most-used medicines in Medicare's prescription drug program are generics, but the program spends the most on brand-name drugs, led by the heartburn treatment Nexium.

TESARO Announces Q1 Operating Results

May 1, 2015 10:53 am | by TESARO | News | Comments

TESARO, Inc., an oncology-focused biopharmaceutical company, today reported operating results for first-quarter 2015 and provided an update on the Company's development programs.

Prostate Cancer Treatment Market To Grow To $8.2 Billion

April 30, 2015 11:46 am | News | Comments

The global treatment market value for prostate cancer will expand more than threefold by 2023.

Flexion Therapeutics Awarded DoD Grant

April 30, 2015 11:38 am | by Flexion Therapeutics | News | Comments

Flexion Therapeutics announced a DoD grant for a clinical trial investigating FX006 as treatment for osteoarthritis ("OA") pain in military personnel.

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.